Concurrent chemoradiation in carcinoma of the uterine cervix

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Carcinoma of the cervix is most commonly treated with radiotherapy when the disease is locally advanced. Tumor bulk often limits the efficacy of this therapy, as does the tolerance of adjacent healthy tissue. Cytotoxic chemotherapeutic agents have been used with concomitant radiotherapy. Extensive data are available on dose and schedule tolerance for cisplatin, 5-fluorouracil, and a number of combination regimens. Phase III data that confirm any advantage in terms of local control, disease-free survival, or overall survival have been published only for hydroxyurea. Hydroxyurea, an S-phase-specific inhibitor of ribonucleotide reductase, lacks single-agent activity against metastatic, squamous cell cervical cancer. Further studies are required before agents other than hydroxyurea can be considered standard therapy with concomitant radiotherapy for locally advanced carcinoma of the cervix.

Original languageEnglish
Pages (from-to)88-91
Number of pages4
JournalSeminars in Oncology
Volume19
Issue number4 SUPPL. 11
StatePublished - 1992

Fingerprint

Hydroxyurea
Cervix Uteri
Radiotherapy
Carcinoma
Ribonucleotide Reductases
Squamous Cell Neoplasms
Cytotoxins
S Phase
Fluorouracil
Uterine Cervical Neoplasms
Cisplatin
Disease-Free Survival
Appointments and Schedules
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Concurrent chemoradiation in carcinoma of the uterine cervix. / Stehman, Frederick.

In: Seminars in Oncology, Vol. 19, No. 4 SUPPL. 11, 1992, p. 88-91.

Research output: Contribution to journalArticle

@article{796157cfd4a14f04853e82c3d0f105a1,
title = "Concurrent chemoradiation in carcinoma of the uterine cervix",
abstract = "Carcinoma of the cervix is most commonly treated with radiotherapy when the disease is locally advanced. Tumor bulk often limits the efficacy of this therapy, as does the tolerance of adjacent healthy tissue. Cytotoxic chemotherapeutic agents have been used with concomitant radiotherapy. Extensive data are available on dose and schedule tolerance for cisplatin, 5-fluorouracil, and a number of combination regimens. Phase III data that confirm any advantage in terms of local control, disease-free survival, or overall survival have been published only for hydroxyurea. Hydroxyurea, an S-phase-specific inhibitor of ribonucleotide reductase, lacks single-agent activity against metastatic, squamous cell cervical cancer. Further studies are required before agents other than hydroxyurea can be considered standard therapy with concomitant radiotherapy for locally advanced carcinoma of the cervix.",
author = "Frederick Stehman",
year = "1992",
language = "English",
volume = "19",
pages = "88--91",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 11",

}

TY - JOUR

T1 - Concurrent chemoradiation in carcinoma of the uterine cervix

AU - Stehman, Frederick

PY - 1992

Y1 - 1992

N2 - Carcinoma of the cervix is most commonly treated with radiotherapy when the disease is locally advanced. Tumor bulk often limits the efficacy of this therapy, as does the tolerance of adjacent healthy tissue. Cytotoxic chemotherapeutic agents have been used with concomitant radiotherapy. Extensive data are available on dose and schedule tolerance for cisplatin, 5-fluorouracil, and a number of combination regimens. Phase III data that confirm any advantage in terms of local control, disease-free survival, or overall survival have been published only for hydroxyurea. Hydroxyurea, an S-phase-specific inhibitor of ribonucleotide reductase, lacks single-agent activity against metastatic, squamous cell cervical cancer. Further studies are required before agents other than hydroxyurea can be considered standard therapy with concomitant radiotherapy for locally advanced carcinoma of the cervix.

AB - Carcinoma of the cervix is most commonly treated with radiotherapy when the disease is locally advanced. Tumor bulk often limits the efficacy of this therapy, as does the tolerance of adjacent healthy tissue. Cytotoxic chemotherapeutic agents have been used with concomitant radiotherapy. Extensive data are available on dose and schedule tolerance for cisplatin, 5-fluorouracil, and a number of combination regimens. Phase III data that confirm any advantage in terms of local control, disease-free survival, or overall survival have been published only for hydroxyurea. Hydroxyurea, an S-phase-specific inhibitor of ribonucleotide reductase, lacks single-agent activity against metastatic, squamous cell cervical cancer. Further studies are required before agents other than hydroxyurea can be considered standard therapy with concomitant radiotherapy for locally advanced carcinoma of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0026663210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026663210&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 88

EP - 91

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 11

ER -